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Abstract
Background: Biliary tract carcinoma (BTC) is a fatal malignancy which aggressiveness contrasts sharply with its
relatively mild and late clinical presentation. Novel molecular markers for early diagnosis and precise treatment are
urgently needed. The purpose of this study was to evaluate the diagnostic and prognostic value of promoter
hypermethylation of the SHOX2 and SEPT9 gene loci in BTC.
Methods: Relative DNA methylation of SHOX2 and SEPT9 was quantified in tumor specimens and matched normal
adjacent tissue (NAT) from 71 BTC patients, as well as in plasma samples from an independent prospective cohort
of 20 cholangiocarcinoma patients and 100 control patients. Receiver operating characteristic (ROC) curve analyses
were performed to probe the diagnostic ability of both methylation markers. DNA methylation was correlated to
clinicopathological data and to overall survival.
Results: SHOX2 methylation was significantly higher in tumor tissue than in NAT irrespective of tumor localization
(p < 0.001) and correctly identified 71% of BTC specimens with 100% specificity (AUC = 0.918; 95% CI 0.865–0.971).
SEPT9 hypermethylation was significantly more frequent in gallbladder carcinomas compared to cholangiocarcinomas
(p = 0.01) and was associated with large primary tumors (p = 0.01) as well as age (p = 0.03). Cox proportional hazard
analysis confirmed microscopic residual tumor at the surgical margin (R1-resection) as an independent prognostic
factor, while SHOX2 and SEPT9 methylation showed no correlation with overall survival. Elevated DNA methylation
levels were also found in plasma derived from cholangiocarcinoma patients. SHOX2 and SEPT9 methylation as a marker
panel achieved a sensitivity of 45% and a specificity of 99% in differentiating between samples from patients with and
without cholangiocarcinoma (AUC = 0.752; 95% CI 0.631–0.873).
Conclusions: SHOX2 and SEPT9 are frequently methylated in biliary tract cancers. Promoter hypermethylation of SHOX2
and SEPT9 may therefore serve as a minimally invasive biomarker supporting diagnosis finding and therapy monitoring
in clinical specimens.
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Background
Biliary tract cancers (BTC) comprise aggressive neo-
plasms arising from the epithelial lining of the intra- and
extrahepatic bile ducts as well as the gallbladder. Chol-
angiocarcinoma (CC) and gallbladder carcinoma (GBC)
account for only about 3% of all gastrointestinal malig-
nancies [1]. Nonetheless, during the last decades, a
steady increase in incidence and mortality rates has been
reported for BTC in Europe as well as in the USA [2, 3].
This relatively uncommon malignancy is associated with
an overall poor prognosis. In contrast to other cancer
entities (e.g., breast, prostate, lymphoma), the 5-year sur-
vival rate of BTC has hardly changed during the last
years and is not exceeding the 20% threshold [4–6].
Complete surgical resection with negative histological
margins is the only potentially curative therapy to date
though most patients rapidly develop recurrence even
after R0 resection. Clinical symptoms normally appear
late and most patients are therefore diagnosed in an
advanced stage when a radical surgical resection is no
longer possible [7]. Merely palliative treatment can be
offered to patients with irresectable BTC [7, 8]. Even
high resolution imaging such as computed tomography
(CT) and magnetic resonance imaging (MRI) are some-
times inaccurate. Furthermore, advanced endoscopic tech-
niques including endoscopic ultrasonography fine needle
aspiration (EUS-FNA) biopsy or brush cytology harvested
within endoscopic retrograde cholangiography (ERC) not
always lead to conclusive diagnoses [9, 10]. Moreover,
established serum biomarkers for BTC like CA 19-9 and
CEA have limited sensitivity and specificity in disease de-
tection and response prediction [9, 11].
There is emerging evidence that genetic and epigenetic
alterations play a pivotal role during human carcinogen-
esis [12, 13]. Specific DNA methylation patterns ensure
proper gene expression, thereby regulating various fun-
damental organic processes, such as cellular differenti-
ation and development [14]. Accordingly, aberrant
methylation of CpG dinucleotides has been evidenced as
a hallmark epigenetic alteration in numerous malignant
diseases [14, 15]. Promoter hypermethylation, in particu-
lar, has been linked to transcriptional silencing of tumor
suppressor genes, thus enabling neoplastic cells to prolif-
erate without restriction [15]. In BTC and its precursor
lesions, these epigenetic alterations can be detected with
possible valuable clinical implications [16–29].
The short stature homeobox 2 gene (SHOX2) is lo-
cated on chromosome 3q25→ 3q26.1 [30]. As a tran-
scriptional factor, SHOX2 is known to be involved in
various embryonic developmental processes including
limb formation and cardiac development [31–33]. Aber-
rant DNA methylation of SHOX2 has been extensively
characterized as a biomarker for the diagnosis of lung
cancer. DNA from lung cancer specimens appeared to
be significantly higher methylated at the SHOX2 gene
locus as compared to morphologically normal adjacent
tissue, and a correlation of hypermethylation and gene
amplification has been described [34]. Thus, SHOX2
methylation has been suggested as a biomarker in body
fluids, e.g., blood plasma, bronchial aspirates, ascites, and
pleural effusions [35–41]. Accordingly, a commercially
available in vitro diagnostic test kit, the Epi proLung® BL
Reflex Assay (Epigenomics AG, Berlin, Germany) has been
developed for sensitive assessment of SHOX2 methylation
in bronchial aspirates [38]. Recently, increased SHOX2
methylation levels were also detected in metastatic lymph
node tissue obtained by endobronchial ultrasound with
transbronchial needle aspiration (EBUS-TBNA) per-
formed in patients with lung cancer, further improving the
assessment of nodal status and staging in this entity [42].
Septins are a family of GTP-ase proteins which play a
pivotal role in the cell cycle and cytokinesis [43, 44].
SEPT9, a member of the Septin gene family, has been re-
ported to exhibit both oncogenic and tumor suppressive
properties in tumorigenesis of solid and hematological
malignancies [45]. DNA methylation of SEPT9 has been
widely studied in colorectal cancer (CRC). Tumor DNA
exhibited significantly higher SEPT9 methylation levels
in comparison with matched normal colon epithelium
[46, 47]. Hypermethylation of SEPT9 was also present in
colon adenomas, thus indicating that this epigenetic al-
teration is an early event in the adenoma-carcinoma se-
quence [47]. Methylated SEPT9 has also been detected
in plasma samples from colorectal cancer patients, and
several studies have proposed its biomarker application
for early diagnosis of CRC [46, 48–50]. Furthermore,
SEPT9 was found to be frequently methylated in the
head and neck and esophageal squamous cell carcinoma,
as well as prostate cancer [51–53]. Recently, a panel of
four DNA methylation markers including SEPT9 has
been reported to aid in the diagnosis of cholangiocarci-
noma in tissue as well as biliary brush samples [16].
Methylation status of SHOX2 and SEPT9 and their
possible clinical implication has hardly been investigated
in BTC. Due to the encouraging results found in other
cancer entities, we hypothesize that these epigenetic al-
terations can serve as biomarkers in cancers arising from
the biliary tract. Our long-term goal is to identify novel
biomarkers for diagnostic and prognostic purposes to
support and individualize treatment of this fatal disease.
Methods
This study was conducted with approval of the Institutional
Review Board (IRB) at the University of Bonn, Germany.
Tissue samples
A total of 71 patients who underwent surgical resec-
tion for intrahepatic (IHC), perihilar (PHC), or distal
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cholangiocarcinoma (DC) as well as gallbladder carcinoma
(GBC) at the Department of Surgery, University of Bonn,
between January 1st, 1990, and December 31st, 2012, were
enrolled. Inclusion criteria were (a) histological diagnosis
of adenocarcinoma of the biliary tract (BTC); (b) primary
resection of the tumor; (c) R0- or R1-resection; and (d)
availability of archival formalin-fixed paraffin-embedded
tissue blocks (Institute of Pathology, University of Bonn).
All BTCs were staged according to the current edition of
the American Joint Committee on Cancer (AJCC) cancer
staging manual [54]. Relevant demographic and clinico-
pathological data were catalogued. Information on overall
survival was obtained during follow-up visits in the out-
patient clinic of our department, or by contacting patients
or the general practitioners.
Hematoxylin and eosin slides were routinely prepared
from FFPE tissue sections and reviewed under a light
microscope. For each patient, an area with the highest
tumor cellularity was selected, and a punch biopsy of 1-
mm diameter was taken from the respective FFPE block.
A second punch biopsy representing morphologically
normal adjacent tissue (NAT) was performed.
Plasma samples
Preoperative plasma samples were collected prospect-
ively from an independent cohort of 20 patients suffer-
ing from cholangiocarcinoma who underwent surgery
between November 2013 and September 2016 at the De-
partment of Surgery, University of Bonn. Tumor staging
and documentation of relevant data was performed as
mentioned above. Plasma samples from 100 gender- and
age-matched patients who did not have a history of a
malignant tumor served as controls. Written consent
was obtained from all patients.
Preparation of sample DNA
For DNA extraction, bisulfite conversion and subse-
quent purification of genomic DNA from FFPE tissue
biopsies and plasma samples, the innuCONVERT Bi-
sulfite All-In-One Kit as well as the innuCONVERT
Bisulfite Body Fluids Kit (Analytik Jena AG, Jena,
Germany) were used, respectively. All kits were ap-
plied according to the manufacturer’s protocol.
Real-time PCR quantification of SHOX2 and SEPT9 DNA
methylation
Relative DNA methylation of the SHOX2 and SEPT9
locus was quantified by a methylation-specific triplex
qPCR assay as previously described [39]. Methylation
status of the ACTB locus served as the reference.
Oligonucleotides used in the assay are summarized in
Additional file 1: Table S2.
The SHOX2 Amplicon is a 112 bp sequence and con-
tains 11 CpGs. Four CpGs are included in the detection
probe and three in the reverse primer. The SEPT9 Ampli-
con is 60 bp long and contains five CpGs, which are all
covered by the blocking primer. Additionally, three out of
five CpGs are covered by the detection probe. Twenty-five
nanograms of template DNA was used as template DNA
for each single PCR reaction. PCR was carried out using
an Applied Biosystems 7500 Fast Real-Time PCR System
(Life Technologies Corporation, Carlsbad, CA, USA) and
the following temperature profile was applied: 20 min at
95 °C followed by 50 cycles with 2 s at 62 °C, 45 s at 56 °C
(each at 100% ramp rate), and 15 s at 95 °C (at 75% ramp
rate) [39].
Data analyses
The calibrator and all samples were measured in trip-
licate, and a mean average of the CT values was cal-
culated. The ΔΔCT method was used to determine a
relative methylation value for each valid sample as
previously described: ΔΔCTSample =ΔCTSample − ΔCTCali-
brator, where ΔCTSample = CTSample/Methylationquantificationassay
−CTSample/Totalquantificationassay and ΔCTCalibrator = CTCalibra-
tor/Methylationquantificationassay −CTCalibrator/Totalquantificationassay
[55, 56]. Percent methylated reference (PMR) values were
calculated applying the following formula: MethylationSam-
ple = 100% × 2
−ΔΔCT [56]. Quantitative SHOX2 and SEPT9
DNA methylation values were dichotomized by setting a
methylation cut-off. The cut-off was set in order to reduce
the false-positive rate for benign controls to 0% in tissue
specimens and to 1% in plasma specimens. All samples
with PMR values above the cut-off were classified as posi-
tive, while samples with methylation values below the cut-
off were classified as negative.
Statistical analyses
Statistical analysis was performed using the SPSS software
version 22 (IBM, Armonk, NY, USA) and GraphPad Prism
6 (GraphPad Software Inc., San Diego, CA, USA).
Mann-Whitney U test was applied to test for differ-
ences in DNA methylation levels between the two
groups. Bonferroni correction was used in case of mul-
tiple pairwise comparisons. Pearson’s correlation be-
tween SHOX2 and SEPT9 methylation was analyzed.
Receiver operating characteristics (ROC) curves were
constructed to investigate the ability of DNA hyperme-
thylation to differentiate between samples from BTC pa-
tients and samples from patients without BTC. The sum
of SHOX2 and SEPT9 DNA methylation values was used
to calculate ROC curves for performance evaluation of
the combined biomarker panel. The area under the ROC
curve (AUC) represents the ability of the test to distin-
guish between patients with and without BTC.
Overall survival was defined as the time between sur-
gery and death or date of last patient contact and used
as primary endpoint for outcome analysis. Univariate
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and multivariate Cox proportional hazard model was ap-
plied to test the association between DNA methylation,
clinicopathological parameters, and overall survival. p
values refer to Wald test. Two-sided p values <0.05 were
considered as statistically significant.
Results
Results from tissue analyses
Patients and tumors
Tissue samples from 71 biliary tract cancers including
42 male (59%) and 29 female (41%) patients with a
median age of 63 years (range 36–83) were analyzed
(clinical and pathological characteristics are listed in
Table 1). Cholangiocarcinomas outnumbered gallblad-
der carcinomas (n = 54, 76% vs. n = 17, 24%). The ma-
jority of cholangiocarcinomas were IHC (n = 25, 35%).
Only five tumors (7%) were well differentiated (G1),
while the remaining were graded as moderately (G2)
or poorly differentiated (G3) (n = 33, 46.5% each).
Most BTC were locally advanced and classified as T3
(n = 38, 53.5%). Positive regional lymph nodes were
found in 16 patients (22.5%), while intrahepatic me-
tastases were present in six patients upon final hist-
ology (M1; 8.5%). Accordingly, the majority of tumors
was staged as UICC III (n = 28, 39%). R0-resection
was achieved in most of patients (n = 52, 73%).
DNA methylation levels of SHOX2 and SEPT9
Percent methylated reference (PMR) values of the
SHOX2 and SEPT9 gene obtained by quantitative
methylation-specific real-time PCR are illustrated in
Fig. 1. Valid measurements were obtained from 55 BTC
and 41 NAT specimens. The performance of both
methylation markers in differentiating tumor tissue from
NAT was evaluated in all 55 BTC specimens collectively,
as well as in CC (n = 43) and GBC (n = 12) individually.
Background methylation with a maximum of 2.52%
(SHOX2) and 2.32% (SEPT9) was present in most NAT
samples, thus necessitating cut-offs for both gene loci to
classify samples as either methylated or unmethylated.
SHOX2 showed significantly higher DNA methylation
values in BTC specimens and both subpopulations com-
pared to NAT (Fig. 1a, b). Among 55 BTC specimens,
39 were correctly rated as SHOX2 positive, resulting in a
sensitivity of 71% with 100% specificity. SHOX2 methyla-
tion frequencies in CC and GBC were 72 and 67%, respect-
ively. No significant difference in SHOX2 methylation
levels was observed between CC and GBC (Fig. 1b).
Elevated SEPT9 DNA methylation levels were also
found in BTC specimens compared to NAT. However,
the results were not statistically significant (Fig. 1c).
Sixteen BTC samples showed SEPT9 positivity, pro-
viding a sensitivity and specificity of 29 and 100%, re-
spectively. If analyzed separately, however, carcinomas
Table 1 Clinicopathological data of 71 biliary tract cancer
patients included in the tissue study. Associations of
clinicopathological data with relative DNA methylation of




methylationClinicopathological data n (%)




PHC (Klatskin tumor) 22 (31)
DC 7 (10)




Male vs. female 0.10 (55) 0.14 (55)
Age at diagnosis
≤60 years 31 (44)
>60 years 40 (56)
Median age [years] 63 NA
Mean age [years] 62 NA
Range [years] 36–83 NA






















V0 vs. V1 0.97 (48) 0.76 (48)
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of the gallbladder presented significantly higher SEPT9
methylation levels than both NAT and CC (Fig. 1d). While
the methylation frequency of SEPT9 reached only 19% in
CC, it was as high as 67% in GBC.
In a further step, the combined performance of
SHOX2 and SEPT9 as a biomarker panel was evaluated.
This panel was considered positive if at least one of both
genes displayed DNA hypermethylation. Since high
methylation values of SHOX2 did not correlate signifi-
cantly with SEPT9 hypermethylation (Pearson’s
correlation coefficient r = 0.24, p value = 0.08), the com-
bined panel was expected to detect more cancer speci-
mens than SHOX2 or SEPT9 alone. As anticipated, the
panel correctly identified 75, 74, and 75% of BTC, CC,
and GBC specimens, respectively. All 41 NAT samples
were rated as SHOX2 and SEPT9 negative, resulting in a
specificity of 100%. The ROC curves and AUC values for
SHOX2, SEPT9, and the combined panel in BTC as well
as in CC and GBC specimens are illustrated in Fig. 2.
Three BTC samples showed relative SHOX2 DNA
methylation values above the theoretically expected
maximum of 100% (109.2, 127.6, and 140.8%). Similarly
high SEPT9 methylation levels were also found in two
other cases (129.7 and 183.8%). Relative SHOX2 and
SEPT9 DNA methylation values were determined by a
triplex assay, which included a reference PCR of the
ACTB gene to quantify the total amount of DNA. PMR
values >100% have been previously reported for SHOX2
in lung cancer, when ACTB was used as a reference, and
were attributed to amplification of the SHOX2 locus or
deletion of the ACTB locus [34, 36, 56]. Therefore, we
presume that deletion of the ACTB locus or amplifica-
tion of the SHOX2 and SEPT9 locus, respectively, may
have also led to PMR values >100% in these five BTC
samples.
Association of DNA methylation with clinicopathological
parameters
Elevated SEPT9 methylation levels correlated signifi-
cantly with advanced size of the primary tumor (T1/T2
vs. T3/T4, p = 0.013) as well as patient age (≤60 years vs.
> 60 years, p = 0.031) (Table 1). However, no significant
association was found between SHOX2 or SEPT9 methy-
lation and the remaining clinicopathological parameters.
Survival analyses
Data on overall survival were available for all 71 patients.
Median follow-up was 15 months (range 0–104 months),
and 50 patients (70%) deceased during the follow-up
time. Results from uni- and multivariate Cox propor-
tional hazards analyses are shown in Table 2. Univariate
survival analysis revealed that lymph node involvement
(p = 0.031, HR = 2.2), lymphatic invasion (p = 0.007, HR
= 2.4), and surgical margin status (p < 0.001, HR = 3.5)
were of prognostic significance. On multivariate analysis
merely microscopic residual carcinoma at the final surgi-
cal margin (R1) proved to be an independent prognostic
factor associated with a dismal outcome (p = 0.026, HR
= 3.8). DNA methylation status of SHOX2 and SEPT9 in
tumor tissue showed no correlation with overall survival.
Results from plasma analyses
DNA from plasma samples taken preoperatively from 20
cholangiocarcinoma patients, and 100 matched controls
Table 1 Clinicopathological data of 71 biliary tract cancer
patients included in the tissue study. Associations of
clinicopathological data with relative DNA methylation of














M0 vs. M1 0.32 (55) 0.36 (55)
UICC stage
UICC I 4 (6)
UICC II 9 (13)
UICC III 28 (39)
UICC IV 10 (14)
Unknown 20 (28)




R0 vs. R1 0.24 (55) 0.66 (55)
Follow-up
Follow-up available 71 (100)
Median follow-up [months] 15 NA
Mean follow-up [months] 23 NA
Range [months] 0–104 NA
Deceased 50 (70)
Censored 21 (30)
p values refer to the Mann-Whitney U test
*p < 0.05
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was analyzed for relative SHOX2 and SEPT9 DNA
methylation (see Additional file 2: Table S1 for clinico-
pathological characteristics of both cohorts). Valid mea-
surements were obtained from all 120 plasma samples,
and respective PMR values are shown in Fig. 3. As in tis-
sue analyses, detectable background methylation in
samples from benign controls required a cut-off for
dichotomization.
SHOX2 DNA methylation was significantly higher in
plasma specimens from CC patients than from controls
and correctly identified 35% (7/20) of carcinoma cases
(Fig. 3a). One control sample was falsely classified as
Fig. 1 SHOX2 and SEPT9 DNA methylation levels in tissue samples. Relative DNA methylation values (PMR in %) of SHOX2 are depicted as black
rhombuses for a NAT and BTC specimens, as well as for b NAT, CC, and GBC specimens. PMR values of SEPT9 are also depicted for c NAT and BTC
specimens, as well as for d NAT, CC, and GBC specimens. Horizontal lines indicate median PMR values of sample series. p values refer to
Mann-Whitney U test. *Bonferroni corrected p values for multiple pairwise compare
Fig. 2 Receiver operating characteristic (ROC) curves for SHOX2, SEPT9, and the combined biomarker panel (based on the sum of PMR values) in
tissue specimens. The ROC curves and resulting area under the curve (AUC) values are depicted for a all 55 BTC specimens: AUC—SHOX2 = 0.918
[95% CI 0.865–0.971]; AUC—SEPT9= 0.601 [95% CI 0.488–0.713]; AUC—Panel 0.933 [95% CI 0.886–0.979] b 43 CC specimens: AUC—SHOX2= 09.21
[0.863–0.979]; AUC—SEPT9= 0,.541 [95% CI 0.416–0.666]; AUC—Panel = 0.932 [95% CI 0.880–0.984] and c 12 GBC specimens: AUC—SHOX2 = 0.907
[95% CI 0.808–1.005]; AUC—SEPT9= 0.815 [95% CI 0.637–0.993]; AUC—Panel = 0.935 [95% CI 0.855–1.015], respectively
Branchi et al. Clinical Epigenetics  (2016) 8:133 Page 6 of 11
SHOX2 positive, resulting in 99% specificity. The area
under the curve (AUC) was 0.691 (95% CI 0.554–0.828).
Similarly, plasma samples from patients with CC showed
increased PMR values of the SEPT9 gene locus (Fig. 3b).
Five plasma samples showed SEPT9 methylation values
above the cut-off, resulting in a sensitivity of 25% with 99%
specificity and an AUC of 0.699 (95% CI 0.561–0.837).
As in tumor tissue, no correlation between SHOX2 and
SEPT9 DNA methylation was observed (Pearson’s correl-
ation coefficient r = 0.072, p = 0.76). Therefore, SHOX2
and SEPT9 as a panel displayed a higher sensitivity than
both gene loci. Nine out of 20 cholangiocarcinoma cases
(45%) were detected, while 99% of control samples were
accurately classified as SHOX2 and SEPT9 negative. The
Table 2 Results from univariate and multivariate survival analyses (Cox proportional hazard models)
Number of patients Hazard ratio [95% CI] p value (Wald test)
Univariate analysis
Tumor location (GBC vs. CC) 71 0.9 [0.5–1.8] 0.83
Gender (Male vs. female) 71 1.4 [0.8–2.5] 0.22
Age at diagnosis (≤60 vs. >60 years) 71 1.1 [0.6–2.0] 0.72
Tumor grade (G1, G2 vs. G3) 71 1.6 [0.9–2.7] 0.13
Tumor stage (T1, T2 vs. T3, T4) 71 1.0 [0.6–1.8] 0.94
Lymph node status (N1, N2 vs. N0) 48 2.2 [1.1–4.5] 0.031*
Venous invasion (V0 vs. V1) 61 1.3 [0.7–2.5] 0.42
Lymphatic invasion (L1 vs. L0) 54 2.4 [1.3–4.6] 0.007*
Perineural invasion (Pn0 vs. Pn1) 52 1.3 [0.6–2.5] 0.50
Distant metastases (M0 vs. M1) 71 2.4 [0.9–6.1] 0.08
UICC stage (UICC I, II vs. UICC III, IV) 51 1.0 [0.5–2.0] 0.91
Surgical margin (R1 vs. R0) 71 3.5 [1.8–6.7] <0.001*
SHOX2 methylationa 55 1.0 [1.0–1.0] 0.52
SEPT9 methylationa 55 1.0 [1.0–1.0] 0.78
SHOX2 methylation (SHOX2− vs. SHOX2+) 55 1.3 [0.6–2.6] 0.51
SEPT9 methylation (SEPT9− vs. SEPT9+) 55 1.1 [0.6–2.4] 0.72
Multivariate analysis
Lymph node status (N0 vs. N1, N2) 1.5 [0.6–3.5] 0.36
Lymphatic invasion (L0 vs. L1) 34 2.1 [0.9–5.3] 0.11
Surgical margin (R0 vs. R1) 3.8 [1.2–12.2] 0.026*
SHOX2 and SEPT9 DNA methylation levels were analyzed as continuous and dichotomized variables. p values refer to the Wald test
*p < 0.05
aContinuous variable
Fig. 3 Relative DNA methylation values (PMR in %) of a SHOX2 and b SEPT9 in plasma samples from 100 controls and 20 cholangiocarcinoma patients.
Each black rhombus represents a patient sample. Horizontal lines indicate median PMR values of sample series. p values refer to Mann-Whitney U test
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combined biomarker panel achieved an area under the
curve (AUC) of 0.752 (95% CI 0.631–0.873). The ROC
curves and AUC values of SHOX2, SEPT9, and the com-
bined panel in plasma samples from cholangiocarcinoma
patients are shown in Fig. 4
Discussion
Epigenetic alterations such as aberrant DNA methylation
patterns have been extensively studied across multiple
human cancer types, with BTC being no exception.
Genome-wide methylation analyses in CC revealed fre-
quent promoter hypermethylation of homeobox genes, a
gene class known to be involved in various developmen-
tal processes [17, 18]. Recently, Goeppert et al. published
global methylation data for intrahepatic and extrahepatic
CC and identified numerous aberrantly methylated
genes involved in cholangiocarcinogenesis, including
components of the Wnt signaling pathway [19]. Unlike
the above referenced, the majority of studies has focused
on the methylation status of a few specific gene loci and
their capability to distinguish between malignant and be-
nign tissues, biliary brush cytologies, and bile juice speci-
mens [16, 20–28]. In the present study, a similar approach
was followed by selecting two candidate genes for methy-
lation analysis in BTC, namely SHOX2 and SEPT9, which
have been reported to be aberrantly methylated in other
tumor entities. Due to afore evidenced clinical implica-
tions, we sought to evaluate the methylation status of
SHOX2 and SEPT9 and their potential as biomarkers in
tissue and plasma specimens from BTC patients.
To our knowledge, this is the first report of recurrent
SHOX2 hypermethylation in BTC. SHOX2 methylation
status has been previously investigated in other malignant
tissue specimens with varying results. Ninety-six percent
of lung cancer samples showed more pronounced methy-
lation than matched NAT samples from the same patients
[34]. Merely 36% of papillary thyroid carcinomas were
found to be methylated at the SHOX2 locus [57]. We ob-
served a SHOX2 hypermethylation in 71% of BTC speci-
mens while no normal tissue sample harbored this
alteration emphasizing the malignant association.
SEPT9, as part of a four genes panel, has been recently
evaluated as a biomarker for CC in tumor tissue as well
as in biliary brush samples [16]. In tissue specimens,
SEPT9 was described to differentiate between CC and
non-malignant controls with a sensitivity of 26% and a
specificity of 100% (AUC = 0.63) [16]. Our study sup-
ported these results, although we observed SEPT9 to be
slightly less sensitive in CC. This is possibly due to selec-
tion bias in relatively small cohorts of rare entities.
While our samples solely comprised formalin-fixed and
paraffin-embedded tissue, Andresen et al. included fresh
frozen tissue samples, too [16]. In a previous study using
the same CC series, both sample materials were com-
pared and methylation frequencies of CDO1, ZSCAN18,
SFRP1, and DCLK1 were found to be generally lower in
FFPE specimens than in the fresh frozen sample set
while modern sensitive techniques may overcome this
observation [29].
In our study, we demonstrated that the DNA methyla-
tion of SHOX2 and SEPT9 can accurately differentiate
between tumor tissue from BTC patients and normal ad-
jacent tissue with high specificity. However, the perform-
ance of both markers varied markedly in terms of
sensitivity, and SHOX2 outperformed SEPT9 in detecting
BTC by more than double. The results confirm our hy-
pothesis that epigenetic alterations of SHOX2 and SEPT9
may serve as biomarkers to support the detection of
BTC in tissue specimens due to its high specificity, and
a use as biomarkers for response prediction can be dis-
cussed. However, the application of this methylation
panel test in the clinical setting as a diagnostic tool may
be limited because of its limited sensitivity. In order to
overcome the low sensitivity, other biomarkers could be
added to the panel. A recent study identified DNA
methylation level of OPCML and SFRP1 as a potential
diagnostic biomarker in BTC [58]. The AUC value of
OPCML was 0.932 and of SFRP1 was 0.951. The sensi-
tivity and specificity of OPCML were 89 and 100%, re-
spectively, and of SFRP1 were 83.6 and 85.5%. The
analysis of a combined methylation panel including
SFPR1, OPCML, SHOX2, and SEPT9 in plasma could in-
crease the diagnostic value of the methylation panel.
The fact that SHOX2 and SEPT9 show different pro-
moter methylation in BTC plasma specimens also sug-
gests a clinical application for minimally invasive
diagnosis in various clinical samples. Half a century after
Fig. 4 Receiver operating characteristic (ROC) curves and area under
the curve (AUC) values for SHOX2, SEPT9, and the combined biomarker
panel, based on the sum of PMR values, in plasma samples.
AUC—SHOX2 = 0.691 [95% CI 0.554–0.828]; AUC-SEPT9 = 0.699 [95% CI
0.561–0.837]; AUC-Panel = 0.752 [95% CI 0.631–0.873]
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Mendel and Metais discovered the presence of cell-free
nucleic acids in human blood, it has become generally
acknowledged that extracellular DNA from cancer pa-
tients also harbors tumor-related epigenetic alterations
[59]. Accordingly, aberrant methylation of circulating
cell-free DNA has been extensively studied as a bio-
marker in human cancer [60]. To our knowledge, larger
studies on quantification of methylated circulating DNA
in BTC are thus far not published. Herein, we report for
the first time that altered promoter methylation can also
be detected in plasma from patients with cholangiocarci-
noma. SHOX2 and SEPT9 DNA methylation levels
showed a high specificity in differentiating between
plasma from CC patients and controls. However, methy-
lation analysis of SHOX2 and SEPT9 in plasma, naturally
containing circulating DNA from any site of the body,
bears some disadvantages for diagnostic purposes in
BTC. In fact, the amount of methylated DNA derived
from the biliary tract is presumably low in proportion to
total sample DNA. This could explain the limited sensi-
tivity observed in our study. The addition of other estab-
lished biomarker like CA19-9 to this panel could
increase the test sensitivity. This issue should be investi-
gated in future prospective studies in order to asses the
value of this methylation panel as a part of a more com-
plex diagnostic tool.
Interestingly, aberrant DNA methylation patterns
have been observed in bile fluid as well as in biliary
brush cytology specimens and were described to be
capable of differentiating between BTC and benign
controls [16, 25–28]. SEPT9 has recently been re-
ported to achieve a sensitivity of 57% with 100% specificity
in biliary brush samples from CC patients, while respective
tissue samples were methylated in less than 30% [16]. In
our tissue study, SHOX2 methylation proved to be superior
to SEPT9 in terms of sensitivity to correctly identify BTC
specimens. Therefore, it seems reasonable to suggest that
SHOX2 DNA methylation could also serve as biomarker
for BTC in biliary brush samples or bile fluids. Andresen et
al. investigated a four-gene methylation biomarker panel
(CDO1, CNRIP1, SEPT9, and VIM) in biliary brush sample
of patients with CC. This test achieved a 85% sensitivity
and a 98% specificity. Thus, future investigations should
analyze the role of a five-gene panel including CDO1,
CNRIP1, VIM, SEPT9, and SHOX2 as a diagnostic tool in
plasma from patients with BTC.
In our cohort, residual carcinoma at the final histo-
logical margin proved to be the only independent pre-
dictor of survival. This finding is in line with previous
studies linking R1-resection to an unfavorable outcome
in BTC [61–63]. Methylation status of SHOX2 and
SEPT9 showed no relation to overall survival in our co-
hort. Nevertheless, a prognostic value of methylated
SHOX2 and SEPT9 has been reported in the literature,
although the findings were partially ambiguous. For in-
stance, low SHOX2 DNA methylation values predicted a
shorter progression-free survival following resection in
non-small cell lung cancer, whereas hypermethylation of
SHOX2 in pleural effusions was associated with an ad-
verse outcome [39, 56]. Schmidt et al. recently proposed
quantitative measurement of methylated SHOX2 DNA
in plasma as a useful tool to monitor therapy response
in advanced stage lung cancer patients [36]. Further-
more, an increased methylation level of SEPT9 was a
predictor of poor prognosis in esophageal squamous cell
carcinoma, as well as in prostate cancer on androgen
deprivation [52, 53]. Likewise, colorectal cancer patients
with high SEPT9 serum methylation levels at 1-year
follow-up were found to be at high risk of disease recur-
rence [64]. Although these promising findings in other
cancer entities suggested that aberrant SHOX2 and
SEPT9 methylation may also correlate with prognosis in
BTC, our results did not confirm this hypothesis. This
could be attributed to our relatively limited sample num-
ber. Therefore, we recommend further research on the
prognostic value of SHOX2 and SEPT9 DNA methyla-
tion in a larger cohort of BTC patients.
Our study has some limitations: Due to the rareness of
BTC, we only included a limited number of patients, and
CCs were not subgrouped into IHC, PHC, and DC though
distinct differences in methylation profiles have been ob-
served between intrahepatic and extrahepatic CC [22, 23].
Moreover, a subgroup analysis of clinicopathological data
and methylation status separately for CC and GBC was not
performed. The subgroups were not large enough in order
to obtain a sufficient statistical power. Therefore, we did
not perform an association analysis for CC and GBC. Thus,
a larger study cohort, possibly based on a multicenter
approach in a prospective fashion, is needed to more pre-
cisely assess the potential of SHOX2 and SEPT9 methyla-
tion as a biomarker for all four subgroups of biliary tract
cancer. Another limitation of our study is the lack of a tar-
geted sequencing of SHOX2 and SEPT9. This could add
some important information concerning the promoter
methylation status of both genes. Thus, we cannot provide
information about the methylated CpG sites in tumor and
normal tissue. Wasserkort et al. already demonstrated that
hypermethylation of SEPT9 in adenoma and CRC speci-
mens is limited to one of the several CpG islands [47].
Moreover, investigation of intragenic CpGs and alternative
promoters could add valuable information about these two
genes. Therefore, a targeted sequencing should be per-
formed in further studies in order to clarify the methyla-
tion status of SHOX2 and SEPT9 in cancer.
Conclusions
Biliary tract cancer remains a fatal disease; thus, novel
molecular markers enabling early diagnosis, treatment
Branchi et al. Clinical Epigenetics  (2016) 8:133 Page 9 of 11
implementation, and therapy monitoring are urgently
needed. Epigenetic alterations are promising for the de-
velopment of biomarkers in human cancer. In this study,
we showed that the SHOX2 gene locus is frequently
methylated in BTC. In addition, our results confirmed
the presence of aberrant methylation of the SEPT9 locus
in BTC. Together, both markers identified 75% of BTC
specimens with 100% specificity. Furthermore, we dem-
onstrated that methylated SHOX2 and SEPT9 DNA can
be detected in plasma from BTC patients highlighting a
use in clinical samples for minimally invasive diagnostic
applications and therapy monitoring. Future studies are
needed to validate the biomarker capabilities of SHOX2
and SEPT9 in BTC before a possible establishment in
clinical practice.
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